CN115067518A - 一种用于提高肿瘤患者免疫力的组合物 - Google Patents
一种用于提高肿瘤患者免疫力的组合物 Download PDFInfo
- Publication number
- CN115067518A CN115067518A CN202210639141.2A CN202210639141A CN115067518A CN 115067518 A CN115067518 A CN 115067518A CN 202210639141 A CN202210639141 A CN 202210639141A CN 115067518 A CN115067518 A CN 115067518A
- Authority
- CN
- China
- Prior art keywords
- beta
- composition
- hydroxy
- methylbutyrate
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 230000036039 immunity Effects 0.000 title claims abstract description 21
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000006041 probiotic Substances 0.000 claims abstract description 20
- 235000018291 probiotics Nutrition 0.000 claims abstract description 20
- 239000002773 nucleotide Substances 0.000 claims abstract description 16
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 16
- 239000004475 Arginine Substances 0.000 claims abstract description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims description 10
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 230000000529 probiotic effect Effects 0.000 claims description 7
- 241000193749 Bacillus coagulans Species 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229940054340 bacillus coagulans Drugs 0.000 claims description 6
- PVBRXXAAPNGWGE-LGVAUZIVSA-L disodium 5'-guanylate Chemical compound [Na+].[Na+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O PVBRXXAAPNGWGE-LGVAUZIVSA-L 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 235000013896 disodium guanylate Nutrition 0.000 claims description 5
- 235000013890 disodium inosinate Nutrition 0.000 claims description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 4
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical compound [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 claims description 3
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 2
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 claims description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 2
- 229950006790 adenosine phosphate Drugs 0.000 claims description 2
- DJJCXFVJDGTHFX-ZAKLUEHWSA-N uridine-5'-monophosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-ZAKLUEHWSA-N 0.000 claims description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 claims 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- AANLCWYVVNBGEE-IDIVVRGQSA-L Disodium inosinate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 AANLCWYVVNBGEE-IDIVVRGQSA-L 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 239000004198 disodium guanylate Substances 0.000 claims 1
- 239000004194 disodium inosinate Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- DJJCXFVJDGTHFX-XVFCMESISA-L uridine 5'-monophosphate(2-) Chemical compound O1[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-L 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 7
- 238000002512 chemotherapy Methods 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 7
- 229940027941 immunoglobulin g Drugs 0.000 abstract description 6
- 201000007270 liver cancer Diseases 0.000 abstract description 6
- 208000014018 liver neoplasm Diseases 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 229940127554 medical product Drugs 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 11
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 9
- 229960004316 cisplatin Drugs 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 5
- SLIUELDPAPMQIB-IDIVVRGQSA-N [Na].[Na].[C@@H]1([C@H](O)[C@H](O)[C@@H](COP(=O)(O)O)O1)N1C=NC=2C(O)=NC=NC12 Chemical compound [Na].[Na].[C@@H]1([C@H](O)[C@H](O)[C@@H](COP(=O)(O)O)O1)N1C=NC=2C(O)=NC=NC12 SLIUELDPAPMQIB-IDIVVRGQSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000004193 disodium 5'-ribonucleotide Substances 0.000 description 4
- INTPYBRGLGSMRA-WFIJOQBCSA-L disodium cytidine 5'-monophosphate Chemical compound [Na+].[Na+].O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])([O-])=O)O1 INTPYBRGLGSMRA-WFIJOQBCSA-L 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- IERHLVCPSMICTF-ZAKLUEHWSA-N cytidine-5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-ZAKLUEHWSA-N 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- KURVIXMFFSNONZ-WFIJOQBCSA-L disodium;[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(=O)NC(=O)C=C1 KURVIXMFFSNONZ-WFIJOQBCSA-L 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- RAJMXAZJKUGYGW-POYBYMJQSA-N 2',3'-dideoxycytidine-5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)CC1 RAJMXAZJKUGYGW-POYBYMJQSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- RSSRHKDOIOBLBS-WFIJOQBCSA-N [Na].[Na].[C@@H]1([C@H](O)[C@H](O)[C@@H](COP(=O)(O)O)O1)N1C(=O)NC(=O)C=C1 Chemical group [Na].[Na].[C@@H]1([C@H](O)[C@H](O)[C@@H](COP(=O)(O)O)O1)N1C(=O)NC(=O)C=C1 RSSRHKDOIOBLBS-WFIJOQBCSA-N 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940105442 cisplatin injection Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种用于提高肿瘤患者免疫力的组合物，属于医药或食品技术领域。本发明公开的一种用于提高肿瘤患者免疫力的组合物，由以下组分组成：β‑羟基‑β‑甲基丁酸盐、核苷酸、益生菌、谷氨酰胺、亮氨酸、精氨酸。本发明的组合物通过协调作用，可以提高肝癌小鼠化疗后免疫球蛋白G含量，从而提高肿瘤机体的免疫力，能够应用在特殊医学用途肿瘤配方食品或医药产品中，可用于提高机体免疫力及抗肿瘤的辅助治疗。
Description
技术领域
本发明涉及医药或食品技术领域，更具体的说是涉及一种用于提高肿瘤患者免疫力的组合物。
背景技术
β-羟基-β-甲基丁酸盐具有促进肌肉蛋白合成、抑制肌肉蛋白分解、稳定肌纤维膜和增强肌肉再生能力、改善肌肉质量和功能等作用。HMB对顺铂化疗后免疫球蛋白G(IgG)的相关研究并未报道。有相关报道，膳食中添加核苷酸有助于降低肿瘤的发病率，对肝脏修复和调节肠道菌群也有明显作用。但膳食中添加核苷酸对顺铂化疗后提高IgG相关研究并未报道。益生菌是一类对宿主有益的活性微生物，它在维持宿主微生态平衡、改善人类健康发挥积极作用。目前已有多种益生菌被允许用于食品中，如嗜酸乳杆菌、鼠李糖乳杆菌、罗伊氏乳杆菌、副干酪乳杆菌、两歧双歧杆菌等。谷氨酰胺是人或哺乳动物体内含量最丰富的一种游离的条件必需氨基酸，是机体内众多代谢活动的能量来源，对机体各器官功能的正常发挥起着重要的作用。亮氨酸是人体内重要的支链氨基酸，也是人体必需氨基酸之一，在体内不能合成，必须由外源性食物补充得到。对顺铂化疗后食用亮氨酸对肝癌的免疫球蛋白G的相关研究并未发现。精氨酸作为一种特殊的免疫调节因子在肿瘤治疗中备受重视。但食用精氨酸在顺铂化疗后对肝癌免疫球蛋白G的相关研究并未报道。
因此，提供一种用于提高肿瘤患者免疫力的组合物是本领域技术人员亟需解决的问题。
发明内容
有鉴于此，本发明提供了一种用于提高肿瘤患者免疫力的组合物，主要针对肿瘤负荷者的特点，经过多次实验研究发现将β-羟基-β-甲基丁酸盐、核苷酸、益生菌、谷氨酰胺、亮氨酸、精氨酸的组合物通过配方的比例调整及配方优化，能够有效改善肝癌顺铂化疗后免疫球蛋白G的指标。
为了实现上述目的，本发明采用如下技术方案：
一种用于提高肿瘤患者免疫力的组合物，按重量份计，由以下组分组成：β-羟基-β-甲基丁酸盐0.01-0.53份、核苷酸0.9-98份、益生菌0.01-98份、谷氨酰胺0.7-10.7份、亮氨酸0.5-98份、精氨酸2.3-98份。
进一步，所述β-羟基-β-甲基丁酸盐选自β-羟基-β-甲基丁酸钙、β-羟基-β-甲基丁酸钠、β-羟基-β-甲基丁酸钾中的至少一种。
进一步，所述核苷酸选自5’-单磷酸胞苷、5’-单磷酸尿苷、5’-单磷酸腺苷、5’-肌苷酸二钠、5’-鸟苷酸二钠、5’-尿苷酸二钠、5’-胞苷酸二钠、麦芽糊精中的至少一种。
进一步，所述益生菌的活力单位为106-1014CFU/g；所述益生菌选自凝结芽孢杆菌、两歧双歧杆菌、嗜酸乳杆菌、鼠李糖乳杆菌、罗伊氏乳杆菌、副干酪乳杆菌中的至少一种。
进一步，一种用于提高肿瘤患者免疫力的组合物的制备方法，包括如下步骤：
(1)将所述原料过30目筛；
(2)将步骤(1)过筛后的原料在混料机中混合30分钟。
经由上述的技术方案可知，与现有技术相比，本发明公开提供了一种用于提高肿瘤患者免疫力的组合物，该组合物通过协调作用，可以提高肝癌小鼠化疗后免疫球蛋白G含量，从而提高肿瘤机体的免疫力，能够应用在特殊医学用途肿瘤配方食品或医药产品中，可用于提高机体免疫力及抗肿瘤的辅助治疗。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
凝结芽孢杆菌、两歧双歧杆菌、嗜酸乳杆菌、鼠李糖乳杆菌、罗伊氏乳杆菌、副干酪乳杆菌均为市售菌株。
实施例1
一种用于提高肿瘤患者免疫力的组合物，按重量份计，由以下组分组成：β-羟基-β-甲基丁酸盐0.53g、核苷酸98g、益生菌98g、谷氨酰胺10.7g、亮氨酸98g、精氨酸98g。
β-羟基-β-甲基丁酸盐为β-羟基-β-甲基丁酸钙。
益生菌选自副干酪乳杆菌，活力单位为1014CFU/g。
核苷酸选自括5’-胞苷酸二钠40％、5’-尿苷酸二钠8％、5’-鸟苷酸二钠7％、5’-单磷酸胞苷6％、5’-肌苷酸二钠5％、麦芽糊精34％。
上述用于肿瘤的组合物的制备方法，包括如下步骤：
(1)将上述原料过30目筛；
(2)将步骤(1)过筛后的原料在混料机中混合30分钟。
实施例2
一种用于提高肿瘤患者免疫力的组合物，按重量份计，由以下组分组成：β-羟基-β-甲基丁酸盐0.01g、核苷酸0.9g、益生菌0.01g、谷氨酰胺0.7g、亮氨酸0.5g、精氨酸2.3g。
β-羟基-β-甲基丁酸盐为β-羟基-β-甲基丁酸钠。
益生菌选自罗伊氏乳杆菌，活力单位为106CFU/g。
核苷酸选自5’-尿苷酸二钠8.067％、5’-鸟苷酸二钠7.267％、5’-单磷酸胞苷6.067％、5’-肌苷酸二钠45.267％，麦芽糊精33.332％。
上述用于肿瘤的组合物的制备方法同实施例1。
实施例3
一种用于提高肿瘤患者免疫力的组合物，按重量份计，由以下组分组成：β-羟基-β-甲基丁酸盐0.23g、核苷酸29g、益生菌5g、谷氨酰胺5g、亮氨酸30g、精氨酸35g。
β-羟基-β-甲基丁酸盐为β-羟基-β-甲基丁酸钾。
益生菌选自副干酪乳杆菌(活力单位为108CFU/g)2.6g和凝结芽孢杆菌(活力单位为108CFU/g)2.4g。
核苷酸选自5’-胞苷酸二钠40％、5’-鸟苷酸二钠10％、5’-肌苷酸二钠10％，麦芽糊精40％。
上述用于肿瘤的组合物的制备方法同实施例1。
对比例1
一种用于肿瘤的组合物，按重量份计，由以下组分组成：β-羟基-β-甲基丁酸盐30g、核苷酸29g、益生菌29g。
β-羟基-β-甲基丁酸盐为β-羟基-β-甲基丁酸钾。
核苷酸选自5’-胞苷酸二钠40％、5’-鸟苷酸二钠10％、5’-肌苷酸二钠10％，麦芽糊精40％。
益生菌选自副干酪乳杆菌(活力单位为108CFU/g)15g和凝结芽孢杆菌(活力单位为108CFU/g)14g。
上述用于肿瘤的组合物的制备方法同实施例1。
对比例2
一种用于肿瘤的组合物，按重量份计，由以下组分组成：β-羟基-β-甲基丁酸盐0.23g、益生菌5g、谷氨酰胺5g、亮氨酸30g、精氨酸35g。
β-羟基-β-甲基丁酸盐为β-羟基-β-甲基丁酸钾。
益生菌选自副干酪乳杆菌(活力单位为108CFU/g)2g和凝结芽孢杆菌(活力单位为108CFU/g)3g。
上述用于肿瘤的组合物的制备方法同实施例1。
对比例3
将北京科奥协力饲料有限公司的大小鼠维持饲料作为对比例3样品。
制备方法同实施例1。
选择SPF级KM小鼠30只，接种肝癌H22细胞，雌雄各半，体重为18g-22g。环境温度为20℃-26℃，湿度为40％-70％，待负荷瘤成功生长形成。小鼠分为实施例1样品组、实施例2样品组、实施例3样品组、对比例1样品组、对比例2样品组、对比例3样品组(模型组)，每组各5只。第1-16天，每天每组小鼠分别按组喂食10g/kg.BW制备的样品1次，并第4天注射顺铂溶液1次及第11天注射顺铂溶液1次(顺铂溶液：将5mg/mL顺铂注射液用生理盐水配成2.5mg/mL顺铂溶液；第4天和第11天的注射剂量均为2.4mL/kg)，第16天，取外周血，加入抗凝剂，离心，取上清，置-80℃冰箱备用。
各组小鼠血清中每只小鼠IgG的含量(ng/ml)结果如下：
各组小鼠血清中IgG的平均含量(ng/ml)如下：
上述结果表明，实施例1样品组与对比例1、2、3样品组比较，IgG分别提高24.95％，24.86％，31.13％；实施例2样品组与对比例1、2、3样品组比较，IgG分别提高26.55％，26.46％，32.80％；实施例3样品组与对比例1、2、3样品组比较，IgG分别提高61.32％，61.21％，69.29％。
从对比中可以看出，实施例1、2、3样品组与对比例1、2、3样品组比较，IgG均有较大的提高。
本发明组分可以添加在特医食品或药品组分中，可提高机体免疫力，同时具有实用性。
对所公开的实施例的上述说明，使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的，本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下，在其它实施例中实现。因此，本发明将不会被限制于本文所示的这些实施例，而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (4)
1.一种用于提高肿瘤患者免疫力的组合物，其特征在于，按重量份计，由以下组分组成：β-羟基-β-甲基丁酸盐0.01-0.53份、核苷酸0.9-98份、益生菌0.01-98份、谷氨酰胺0.7-10.7份、亮氨酸0.5-98份、精氨酸2.3-98份。
2.根据权利要求1所述的一种用于提高肿瘤患者免疫力的组合物，其特征在于，所述β-羟基-β-甲基丁酸盐选自β-羟基-β-甲基丁酸钙、β-羟基-β-甲基丁酸钠、β-羟基-β-甲基丁酸钾中的至少一种。
3.根据权利要求1所述的一种用于提高肿瘤患者免疫力的组合物，其特征在于，所述核苷酸选自5’-单磷酸胞苷、5’-单磷酸尿苷、5’-单磷酸腺苷、5’-肌苷酸二钠、5’-鸟苷酸二钠、5’-尿苷酸二钠、5’-胞苷酸二钠、麦芽糊精中的至少一种。
4.根据权利要求1所述的一种用于提高肿瘤患者免疫力的组合物，其特征在于，所述益生菌的活力单位为106-1014CFU/g；所述益生菌选自凝结芽孢杆菌、两歧双歧杆菌、嗜酸乳杆菌、鼠李糖乳杆菌、罗伊氏乳杆菌、副干酪乳杆菌中的至少一种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210639141.2A CN115067518A (zh) | 2022-06-07 | 2022-06-07 | 一种用于提高肿瘤患者免疫力的组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210639141.2A CN115067518A (zh) | 2022-06-07 | 2022-06-07 | 一种用于提高肿瘤患者免疫力的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115067518A true CN115067518A (zh) | 2022-09-20 |
Family
ID=83251580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210639141.2A Pending CN115067518A (zh) | 2022-06-07 | 2022-06-07 | 一种用于提高肿瘤患者免疫力的组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115067518A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115644436A (zh) * | 2022-10-28 | 2023-01-31 | 浙江蓝美技术股份有限公司 | 适合肿瘤化疗致虚弱人群使用的复方营养制剂及其制备方法和应用 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1810238A (zh) * | 2005-01-24 | 2006-08-02 | 姜广良 | 精氨酸口服配方预防和治疗恶液质综合症 |
| CN101524155A (zh) * | 2009-04-20 | 2009-09-09 | 北京康比特体育科技股份有限公司 | 一种氨基酸组合物 |
| US20110229447A1 (en) * | 2008-09-19 | 2011-09-22 | Eduardo Schiffrin | Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
| CN104302285A (zh) * | 2012-01-11 | 2015-01-21 | 雅培制药有限公司 | 用于治疗糖尿病性溃疡的β-羟基-β-甲基丁酸盐、精氨酸和谷氨酰胺的组合产品 |
| CN108391811A (zh) * | 2018-03-05 | 2018-08-14 | 北京诺康达医药科技有限公司 | 一种肿瘤全营养配方食品及其应用 |
| CN111436601A (zh) * | 2020-05-11 | 2020-07-24 | 上海复旦奥医医学科技有限公司 | 一种胰腺癌专用型临床营养配方及其制备 |
| CN111480839A (zh) * | 2020-03-26 | 2020-08-04 | 上海复旦奥医医学科技有限公司 | 一种骨癌专用型临床营养配方及其制备方法 |
| CN113615837A (zh) * | 2021-07-30 | 2021-11-09 | 珍奥集团股份有限公司 | 一种延缓衰老的核苷酸益生菌胶囊 |
-
2022
- 2022-06-07 CN CN202210639141.2A patent/CN115067518A/zh active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1810238A (zh) * | 2005-01-24 | 2006-08-02 | 姜广良 | 精氨酸口服配方预防和治疗恶液质综合症 |
| US20110229447A1 (en) * | 2008-09-19 | 2011-09-22 | Eduardo Schiffrin | Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
| CN101524155A (zh) * | 2009-04-20 | 2009-09-09 | 北京康比特体育科技股份有限公司 | 一种氨基酸组合物 |
| CN104302285A (zh) * | 2012-01-11 | 2015-01-21 | 雅培制药有限公司 | 用于治疗糖尿病性溃疡的β-羟基-β-甲基丁酸盐、精氨酸和谷氨酰胺的组合产品 |
| CN108391811A (zh) * | 2018-03-05 | 2018-08-14 | 北京诺康达医药科技有限公司 | 一种肿瘤全营养配方食品及其应用 |
| CN111480839A (zh) * | 2020-03-26 | 2020-08-04 | 上海复旦奥医医学科技有限公司 | 一种骨癌专用型临床营养配方及其制备方法 |
| CN111436601A (zh) * | 2020-05-11 | 2020-07-24 | 上海复旦奥医医学科技有限公司 | 一种胰腺癌专用型临床营养配方及其制备 |
| CN113615837A (zh) * | 2021-07-30 | 2021-11-09 | 珍奥集团股份有限公司 | 一种延缓衰老的核苷酸益生菌胶囊 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115644436A (zh) * | 2022-10-28 | 2023-01-31 | 浙江蓝美技术股份有限公司 | 适合肿瘤化疗致虚弱人群使用的复方营养制剂及其制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10124016B2 (en) | Immune system stimulating nutrition | |
| AU2014350144B2 (en) | Compositions for use in the prevention or treatment of URT infections in infants or young children at risk | |
| KR101493302B1 (ko) | 선택된 비병원성 미생물에 의한 천연 폴리사카라이드의 프로세싱 및 이의 제조 방법 및 사용 방법 | |
| CN114532538A (zh) | 用于预防或治疗婴儿或幼儿的耳炎或支气管炎的组合物 | |
| JPS615022A (ja) | 腸内細菌叢改善剤 | |
| AU2014350419A1 (en) | Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by C-section | |
| WO2017129650A1 (en) | Compositions comprising 2fl and lnnt for use in infants or young children to prevent later in life obesity or related comorbidities | |
| CN111903766A (zh) | 一种婴幼儿配方奶粉及其制备方法 | |
| CN115067518A (zh) | 一种用于提高肿瘤患者免疫力的组合物 | |
| CN105744939A (zh) | 用于治疗或预防流行性感冒感染的含有2-岩藻糖基化低聚糖的婴儿配方食品 | |
| JP4369258B2 (ja) | 免疫賦活剤 | |
| CN115944665A (zh) | 一种改善肠道菌群平衡的益生菌剂及其制备方法和应用 | |
| CN112741334B (zh) | 益生元组合物、组合物及其用途 | |
| JP4064515B2 (ja) | Ｉｌ−１２産生誘導組成物 | |
| CN108403970B (zh) | 一种益生元组合物及其制备方法和应用 | |
| CN114146120B (zh) | 一种预防及治疗萎缩性胃炎的组合物微胶囊及其制备方法 | |
| CN115040549A (zh) | 一种用于肿瘤的组合物 | |
| JPS6316118B2 (zh) | ||
| Bhatia et al. | Coencapsulation of synbiotics for the evaluation of in vivo antidiabetic activity | |
| JPH0892112A (ja) | サイトカイン産生促進剤 | |
| CN114984065A (zh) | 一种提高免疫力的益生菌组合物及其制备方法 | |
| CN115040550A (zh) | 一种用于提高免疫球蛋白g的组合物 | |
| JP4782385B2 (ja) | 免疫賦活剤 | |
| CN114806920B (zh) | 一种双歧杆菌的培养基及其培养方法与应用 | |
| JPS5953835B2 (ja) | ビフイズス菌用選択的糖源 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220920 |
|
| RJ01 | Rejection of invention patent application after publication |